MichaelGlenKauffmanMDPhD

PubMed

• 236 citations
  CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications.
  Yu-Tzu Tai, Yosef Landesman, Chirag Acharya, Yolanda Calle, Mike Y Zhong
  Leukemia. 2014-01-01
• 169 citations
  Prognostic impact and targeting of CRM1 in acute myeloid leukemia.
  Kensuke Kojima, Steven M. Kornblau, Vivian Ruvolo, Archana Dilip, Seshagiri Duvvuri
  Blood. 2012-11-16
• 142 citations
  KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute ...
  Julia Etchin, Takaomi Sanda, Marc R. Mansour, Alex Kentsis, Joan Montero
  British Journal of Haematology. 2013-04-01

Abstracts/Posters

• Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacy...
  Michael G. Kauffman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
  Michael G. Kauffman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)
  Michael G. Kauffman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study
  Michael G. Kauffman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome
  Michael G. Kauffman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
  Michael G. Kauffman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma
  Michael G. Kauffman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018